Lucid Diagnostics News

Buy Rating Affirmed for Lucid Diagnostics Amid Positive Financial and Clinical Milestones

TipRanks03:05

Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $3 Price Target

Cantor Fitzgerald analyst Ross Osborn reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Overweight and maintains $3 price target.

BenzingaMay 15 20:25

Lucid Diagnostics (LUCD) Gets a Buy From Cantor Fitzgerald

TipRanksMay 15 19:15

Lucid Diagnostics: A Buy Rating on Operational Growth and Strategic Milestones

TipRanksMay 14 19:36

Lucid Diagnostics Insights: Performance and Outlook Update

TipRanksMay 14 18:23

Press Release: PAVmed Provides Business Update and First Quarter 2024 Financial Results

PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting

Dow JonesMay 14 08:43

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Jasper Therapeutics (JSPR) and Lucid Diagnostics (LUCD)

TipRanksMay 13 23:50

Lucid Diagnostics | 10-Q: Quarterly report

SEC announcementMay 13 20:24 · Announcements

Lucid's Chairman And CEO Says We Strengthened Balance Sheet Closing ~$30M Preferred Stock Financing To Long-Term Investors; Extends Our Runway Past Milestones; EsoGuard Commercial Execution Continues To Deliver Results As We Drive Towards Expanded...

Lucid's Chairman And CEO Says We Strengthened Balance Sheet Closing ~$30M Preferred Stock Financing To Long-Term Investors; Extends Our Runway Past Milestones; EsoGuard Commercial Execution Continues

BenzingaMay 13 20:08

Lucid Diagnostics Q1 2024 Adj EPS $(0.21) Beats $(0.27) Estimate, Sales $1.001M Miss $1.046M Estimate

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 12.5 percent increase over losses of $(0

BenzingaMay 13 20:03

Lucid Diagnostics (LUCD.US): The 2024 Q1 financial report achieved revenue of US$1.01 million, with a previous value of US$446,000 and an expected value of US$1.05 million; earnings per share were -0.21 dollars, previous value was -0.24 dollars, and expec

Lucid Diagnostics (LUCD.US): The 2024 Q1 financial report achieved revenue of US$1.01 million, with a previous value of US$446,000 and an expected value of US$1.05 million; earnings per share were -0.21 dollars, previous value was -0.24 dollars, and expected value was -0.27 dollars.

Zhitong FinanceMay 13 20:03

Lucid Diagnostics Says EsophaCap Device Recalled Due To Recent Publication Of Serious Device Failures

Lucid Diagnostics Says EsophaCap Device Recalled Due To Recent Publication Of Serious Device Failures

BenzingaMay 9 20:23

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireMay 9 19:49

Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale

TipRanksMay 7 20:02

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the

PR NewswireMay 7 19:39

Lucid Diagnostics Highlights Promising EsoGuard Study Results

TipRanksMay 3 05:12

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical

PR NewswireMay 2 20:35

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication fur

PR NewswireMay 2 19:49

12 Health Care Stocks Moving In Monday's After-Market Session

GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings

BenzingaApr 30 04:31

Lucid Diagnostics Partners With the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireApr 29 20:47